London (Reuters) – The Anglo-Swedish drug company AstraZeneca (NASDAQ:AZN) and partner Ionis Pharmaceuticals (NASDAQ:IONSexperimental )’s drug eplontersen met the main goals of a late-stage trial in patients with a rare, fatal disease, the company said on Tuesday.
Based on the results, the companies plan to file an application to sell the therapy to people with hereditary transthyretin-mediated amyloid polyneuropathy in the United States by the end of this year (ATTRv-PN).
